STOCK TITAN

BIOLIFE SOLUTIONS (BLFS) SEC Filings, Oct 6-8, 2026

BLFS

BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.

The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.

Rhea-AI Summary

BioLife Solutions director Catherine Coste disposed of 13,871 shares on October 6, 2026, in connection with the merger; her reported direct holdings afterward were 0 shares. Under the merger terms, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares, subject to the merger agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

BioLife Solutions Inc. Chief Executive Officer and director Roderick de Greef reported two restricted-stock acquisitions and merger-related dispositions on October 6, 2026. The acquisitions were 225,670 shares and 237,460 shares; both awards vested immediately before the merger at approximately 200% of the shares granted, based on total shareholder return relative to certain peers over separate measurement periods ending October 2, 2026.

De Greef disposed of 826,454 shares in connection with the merger. Each outstanding common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Separately, 364,872 shares were withheld for tax obligations in connection with vesting, at $38.61 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

BioLife Solutions (BLFS) director Anthony Hunt reported a disposition of 15,046 common shares on October 6, 2026, in connection with consummation of the First Merger under an agreement involving Repligen Corporation. At the effective time, each outstanding BioLife share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Hunt reported zero direct shares following the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

BioLife Solutions (BLFS) director Timothy L. Moore returned 44,943 shares to the issuer on October 6, 2026, in connection with the consummation of its merger with Repligen Corporation. Under the merger terms, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the Merger Agreement. Moore's reported direct holdings after the disposition were zero shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

BioLife Solutions EVP & Chief Scientific Officer Aby J. Mathew reported acquiring 45,838 and 40,192 shares of restricted stock on October 6, 2026. The awards vested immediately before the merger’s effective time at approximately 200% of the number of shares granted, based on performance comparisons described in the award terms.

Mathew also reported that 70,000 shares were withheld to cover tax obligations, at a reported price of $38.61 per share, and a disposition of 404,608 shares in connection with the merger’s consummation. At the effective time, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported acquiring 38,198 and 40,192 shares of restricted stock on October 6, 2026; both awards vested immediately before the merger’s effective time. Each award vested at approximately 200% of the number of shares granted, based on BioLife’s total shareholder return compared with certain peers over periods beginning January 1, 2025 and January 1, 2026, respectively, through October 2, 2026. Berard also reported that 46,170 shares were withheld to cover tax withholding obligations, with a reported price of $38.61 per share, and that 194,786 shares were disposed of in connection with the merger. Each outstanding BioLife common share converted into a right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement’s terms and conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

BioLife Solutions Chief Technology Officer Sean Werner reported acquiring 45,838 shares and 48,232 shares under restricted-stock awards on October 6, 2026. Both awards vested immediately before the merger effective time at approximately 200% of the number of shares granted, based on BioLife’s total shareholder return compared with certain peers over separate performance periods. Werner also reported 71,226 shares withheld for tax obligations at a reported price of $38.61 per share, and the disposition of 69,979 shares in connection with the consummation of the merger with Repligen Corporation. Under the merger terms, each BioLife common share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

BioLife Solutions, Inc. (BLFS) ended all offerings under its Form S-3 shelf, which had registered up to $75,000,000 in aggregate offering price across common stock, preferred stock, debt securities, warrants, units and rights. It removed from registration all securities under that shelf that remained unsold or otherwise unissued, and terminated the registration statement.

On October 6, 2026, the issuer completed two mergers with wholly owned subsidiaries of Repligen Corporation. BioLife Solutions, Inc. first survived as Repligen’s wholly owned subsidiary; it then merged into Bravo Merger Sub II, which survived as a direct, wholly owned Repligen subsidiary and was renamed BioLife Solutions, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
amendment
-
Rhea-AI Summary

BioLife Solutions, Inc. (BLFS) deregistered all securities that remained unsold or otherwise unissued as of October 6, 2026, under a resale registration statement that previously covered up to 927,165 shares of common stock. The company terminated all offerings under the statement and its effectiveness.

A two-step merger completed October 6, 2026, with a Repligen subsidiary surviving as a direct, wholly owned subsidiary of Repligen and renamed BioLife Solutions, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
amendment
Rhea-AI Summary

BioLife Solutions Inc. (BLFS) is the subject of a Nasdaq Form 25 notification concerning removal of its common stock from listing and registration on the Nasdaq Stock Market. Nasdaq states that it complied with its rules to strike the class from listing, and that the issuer complied with the requirements for voluntary withdrawal. Nasdaq also certifies that it has reasonable grounds to file the notification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many BIOLIFE SOLUTIONS (BLFS) SEC filings are available on StockTitan?

StockTitan tracks 163 SEC filings for BIOLIFE SOLUTIONS (BLFS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BIOLIFE SOLUTIONS (BLFS)?

The most recent SEC filing for BIOLIFE SOLUTIONS (BLFS) was filed on November 16, 2026.